BIOMES
Health prevention based on genomics: because well-being is encoded in our DNA.
Health prevention based on genomics: because well-being is encoded in our DNA.
BIOMES is a biotech startup focusing on health prevention through genomic analysis. Founded in 2017 and headquartered in Germany, the company offers scientific self-testing kits to understand the human microbiome. BIOMES uses high-throughput DNA sequencing, machine learning, and community engagement to analyze the microbiome and provide evidence-based recommendations for individuals to restore their gut balance naturally. The company's flagship product, INTEST.pro, is a DNA-based gut microbiome analysis that offers personalized health insights and actionable recommendations. Through a process that involves sending a stool sample to their lab in Wildau, Germany, BIOMES extracts and analyzes the DNA to empower users to make informed decisions about their well-being. With a focus on Big Data, Biotechnology, Health Care, Health and Wellness, Life Sciences, Nutrition, Clean Energy, and Lifestyle, BIOMES has garnered the attention of investors. In its Corporate Round investment at 20 November 2024, the company secured funding from Keiyo Gas, showcasing the investor interest in the promising capabilities of BIOMES in the genomics and health sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | Unknown | 1 | Keiyo Gas | 20 Nov 2024 |
| Seed Round | €2.00M | 1 | GPS Ventures GmbH | 07 Dec 2020 |
| Seed Round | €2.00M | 1 |
|
13 Feb 2020 |
| Grant | €1.00M | 1 | EXIST | 01 Jan 2017 |
No recent news or press coverage available for BIOMES.
We care about your data, and we'd love to use cookies make your experience better.
